Alexandre Colavin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexandre Colavin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Britt Johnson
GeneDx LLC, Gaithersburg, MD, USA
2 shared publications - Flavia M. Facio
GeneDx LLC, Gaithersburg, MD, USA
2 shared publications - Hillery C. Metz
Department of Ecology and Evolutionary Biology, and Princeton Neuroscience Institute, Princeton University, Princeton, New Jersey 08540, USA
2 shared publications - Keith Nykamp
Invitae Corporation San Francisco California USA
2 shared publications - Robert L. Nussbaum
Invitae Corporation, San Francisco, CA
2 shared publications - Swaroop Aradhya
Invitae Corporation (now part of Labcorp), San Francisco, CA; Illumina, San Diego, CA
2 shared publications
Latest Publications
- 30 September 2023
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 193 (3)
Cover Image, Volume 193, Number 3, September 2023
Cover legend: Aradhya etal., Am J Med Genet C Semin Med Genet 2023, 10.1002/ajmg.c.32057. image
- 30 September 2023
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 193 (3)
Cover Image, Volume 193, Number 3, September 2023
Cover legend: Aradhya etal., Am J Med Genet C Semin Med Genet 2023, 10.1002/ajmg.c.32057. image
- Open Access
- 28 July 2023
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 193 (3)
Applications of artificial intelligence in clinical laboratory genomics
The transition from analog to digital technologies in clinical laboratory genomics is ushering in an era of “big data” in ways that will exceed human capacity to rapidly and reproducibly analyze those data using conventional approaches. Accurately evaluating complex molecular data to facilitate timely diagnosis and management of genomic disorders will require supportive artificial intelligence methods. These are already being introduced into clinical laboratory genomics to identify variants in DNA sequencing data, predict the effects of DNA variants on protein structure and function to inform clinical interpretation of pathogenicity, link phenotype ontologies to genetic variants identified through exome or genome sequencing to help clinicians reach diagnostic answers faster, correlate genomic data with tumor staging and treatment approaches, utilize natural language processing to identify critical published medical literature during analysis of genomic data, and use interactive chatbots to identify individuals who qualify for genetic testing or to provide pre‐test and post‐test education. With careful and ethical development and validation of artificial intelligence for clinical laboratory genomics, these advances are expected to significantly enhance the abilities of geneticists to translate complex data into clearly synthesized information for clinicians to use in managing the care of their patients at scale.
- 28 July 2023
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 193 (3)
Open AccessApplications of artificial intelligence in clinical laboratory genomics
The transition from analog to digital technologies in clinical laboratory genomics is ushering in an era of “big data” in ways that will exceed human capacity to rapidly and reproducibly analyze those data using conventional approaches. Accurately evaluating complex molecular data to facilitate timely diagnosis and management of genomic disorders will require supportive artificial intelligence methods. These are already being introduced into clinical laboratory genomics to identify variants in DNA sequencing data, predict the effects of DNA variants on protein structure and function to inform clinical interpretation of pathogenicity, link phenotype ontologies to genetic variants identified through exome or genome sequencing to help clinicians reach diagnostic answers faster, correlate genomic data with tumor staging and treatment approaches, utilize natural language processing to identify critical published medical literature during analysis of genomic data, and use interactive chatbots to identify individuals who qualify for genetic testing or to provide pre‐test and post‐test education. With careful and ethical development and validation of artificial intelligence for clinical laboratory genomics, these advances are expected to significantly enhance the abilities of geneticists to translate complex data into clearly synthesized information for clinicians to use in managing the care of their patients at scale.